The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Blood‐Brain Barrier Permeable Gold Nanoparticles: An Efficient Delivery Platform for Enhanced Malignant Glioma Therapy and Imaging
Open accessAbstract
The blood‐brain barrier (BBB) remains a formidable obstacle in medicine, preventing efficient penetration of chemotherapeutic and diagnostic agents to malignant gliomas. Here, a transactivator of transcription (TAT) peptide‐modified gold nanoparticle platform (TAT‐Au NP) with a 5 nm core size is demonstrated to be capable of crossing the BBB efficiently and delivering cargoes such as the anticancer drug doxorubicin (Dox) and Gd 3+ contrast agents to brain tumor tissues. Treatment of mice bearing intracranial glioma xenografts with pH‐sensitive Dox‐conjugated TAT‐Au NPs via a single intravenous administration leads to significant survival benefit when compared to the free Dox. Furthermore, it is demonstrated that TAT‐Au NPs are capable of delivering Gd 3+ chelates for enhanced brain tumor imaging with a prolonged retention time of Gd 3+ when compared to the free Gd 3+ chelates. Collectively, these results show promising applications of the TAT‐Au NPs for enhanced malignant brain tumor therapy and non‐invasive imaging.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Stupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., Taphoorn, M. J., Janzer, R. C., Ludwin, S. K., Allgeier, A., Fisher, B., Belanger, K., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70025-7 · Cited by 7,668
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565
Immunotherapy of Diffuse Gliomas: Biological Background, Current Status and Future Developments
Grauer, O. M., Wesseling, P., & Adema, G. J. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00315.x · Cited by 4,007
Wen, P. Y., & Kesari, S. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0708126 · Cited by 3,511
Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment
Hobbs, S. K., Monsky, W. L., Yuan, F., Roberts, W. G., Griffith, L., Torchilin, V. P., & Jain, R. K. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.8.4607 · Cited by 2,438
In Vivo Protein Transduction: Delivery of a Biologically Active Protein into the Mouse
Schwarze, S. R., Ho, A., Vocero-Akbani, A., & Dowdy, S. F. (1999) · Science · doi:10.1126/science.285.5433.1569 · Cited by 2,416
Dysregulated pH: a perfect storm for cancer progression
Webb, B. A., Chimenti, M., Jacobson, M. P., & Barber, D. L. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3110 · Cited by 2,237
Nanoparticle PEGylation for Imaging and Therapy
Jokerst, J. V., Lobovkina, T., Zare, R. N., & Gambhir, S. S. (2011) · Nanomedicine · doi:10.2217/nnm.11.19 · Cited by 2,046
Lewin, M., Carlesso, N., Tung, C.-H., Tang, X.-W., Cory, D., Scadden, D. T., & Weissleder, R. (2000) · Nature Biotechnology · doi:10.1038/74464 · Cited by 1,716
Cited by
Crossing the blood-brain barrier with nanoparticles
Zhou, Y., Peng, Z., Seven, E. S., & Leblanc, R. M. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.12.015 · Cited by 837
“In the experiments related to releasing drugs across the BBB, the mechanism of NPs uptake by the endothelial cells can be divided to passive diffusion [126], carriermediated transport [127], endocytosis such as receptor- [128], and absorption- [50] mediated endocytosis depending on the sizes, charges, and functional g…”
BackgroundNanoparticles in Daily Life: Applications, Toxicity and Regulations
Gupta, R., & Xie, H. (2018) · Journal of Environmental Pathology, Toxicology and Oncology · doi:10.1615/jenvironpatholtoxicoloncol.2018026009 · Cited by 553
Nanoparticles and targeted drug delivery in cancer therapy
Bahrami, B., Hojjat-Farsangi, M., Mohammadi, H., Anvari, E., Ghalamfarsa, G., Yousefi, M., & Jadidi-Niaragh, F. (2017) · Immunology Letters · doi:10.1016/j.imlet.2017.07.015 · Cited by 510
Peptide and protein nanoparticle conjugates: versatile platforms for biomedical applications
Spicer, C. D., Jumeaux, C., Gupta, B., & Stevens, M. M. (2018) · Chemical Society Reviews · doi:10.1039/c7cs00877e · Cited by 497
Progress and perspectives on targeting nanoparticles for brain drug delivery
Gao, H. (2016) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2016.05.013 · Cited by 495
Hersh, A. M., Alomari, S., & Tyler, B. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084153 · Cited by 478
Evolving Drug Delivery Strategies to Overcome the Blood Brain Barrier
S. Hersh, D., S. Wadajkar, A., B. Roberts, N., G. Perez, J., P. Connolly, N., Frenkel, V., A. Winkles, J., F. Woodworth, G., & J. Kim, A. (2016) · Current Pharmaceutical Design · doi:10.2174/1381612822666151221150733 · Cited by 387
Nanocarrier-based drug combination therapy for glioblastoma
Zhao, M., van Straten, D., Broekman, M. L. D., Préat, V., & Schiffelers, R. M. (2020) · Theranostics · doi:10.7150/thno.38147 · Cited by 373
Ligand-installed nanocarriers toward precision therapy
Mi, P., Cabral, H., & Kataoka, K. (2020) · Advanced Materials · doi:10.1002/adma.201902604 · Cited by 350
Development of Pharmaceutical Nanomedicines: From the Bench to the Market
Halwani, A. A. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14010106 · Cited by 324
Blood-Brain Delivery Methods Using Nanotechnology
Teleanu, D. M., Chircov, C., Grumezescu, A. M., Volceanov, A., & Teleanu, R. I. (2018) · Pharmaceutics · doi:10.3390/pharmaceutics10040269 · Cited by 305
Norouzi, M., Yathindranath, V., Thliveris, J. A., Kopec, B. M., Siahaan, T. J., & Miller, D. W. (2020) · Scientific Reports · doi:10.1038/s41598-020-68017-y · Cited by 292
Gold nanoparticles enlighten the future of cancer theranostics
Guo, J., Rahme, K., He, Y., Li, L.-L., Holmes, J., & O'Driscoll, C. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s140772 · Cited by 260
Challenges and opportunities to penetrate the blood-brain barrier for brain cancer therapy
Upton, D. H., Ung, C., George, S. M., Tsoli, M., Kavallaris, M., & Ziegler, D. S. (2022) · Theranostics · doi:10.7150/thno.69682 · Cited by 182
Nanotherapy and Reactive Oxygen Species (ROS) in Cancer: A Novel Perspective
Brenneisen, P., & Reichert, A. (2018) · Antioxidants · doi:10.3390/antiox7020031 · Cited by 105
Zhang, Z.-T., Huang-Fu, M.-Y., Xu, W.-H., & Han, M. (2019) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2019.02.009 · Cited by 82
Wang, L., Shi, Y., Jiang, J., Li, C., Zhang, H., Zhang, X., Jiang, T., Wang, L., Wang, Y., & Feng, L. (2022) · Small · doi:10.1002/smll.202203678 · Cited by 71
Enhanced EGFR Targeting Activity of Plasmonic Nanostructures with Engineered GE11 Peptide
Biscaglia, F., Rajendran, S., Conflitti, P., Benna, C., Sommaggio, R., Litti, L., Mocellin, S., Bocchinfuso, G., Rosato, A., Palleschi, A., et al. (2017) · Advanced Healthcare Materials · doi:10.1002/adhm.201700596 · Cited by 59
Vinod, C., & Jena, S. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.612692 · Cited by 45
Mazzuca, C., Di Napoli, B., Biscaglia, F., Ripani, G., Rajendran, S., Braga, A., Benna, C., Mocellin, S., Gobbo, M., Meneghetti, M., et al. (2019) · Nanoscale Advances · doi:10.1039/c9na00096h · Cited by 16
Batool, S., Nabipour, H., Ramakrishna, S., & Mozafari, M. (2022) · Medical & Biological Engineering & Computing · doi:10.1007/s11517-022-02664-3 · Cited by 15
Metadata
- Authors
- Cheng, Y., Dai, Q., Morshed, R. A., Fan, X., Wegscheid, M. L., Wainwright, D. A., Han, Y., Zhang, L., Auffinger, B., Tobias, A. L., Rincón, E., Thaci, B., Ahmed, A. U., Warnke, P. C., He, C., & Lesniak, M. S.
- Venue
- Small
- Publisher
- Wiley
- Published
- 2014-08-08
- Volume
- 10
- Issue
- 24
- Pages
- 5137-5150
- ISSN
- 1613-6810 (ISSN-L)
- 1613-6829
- OpenAlex
- W2108294913
- Cited by
- 271
- References
- 46
- FWCI
- 6.65
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.